Ampio Pharmaceuticals, Inc. Message Board

P.S. I lost more then Tamara (Pretty Amused) and it hurt. I'm back
here, expecting to break even.

ray, I have the book. I was quoted in it several times. Avanir has had some
terrible management with a movie full of dramatics. You have exposed yourself
as an Avanir disgruntled: ex- employee, investor, or owner. Avanir was lucky with
a lipstick component in Abreva and now with their cough medicine aspirin for
the brain, Nuedexta. Keith Katkin fell on the opportunity at the right time and
made the best of it.. There is a lot of hate for this company out there. Under
KK this is a new company who does what it says it's going to do. Nothing
like the old Avanir. ray, let it go.

Sentiment: Strong Buy

ray, what is shorting against the box? Do you understand the concept? I know it's
usually a tax strategy but these whiz kids and their computers know how to manage
risk with whatever is legal. The shorter against the box has COMPLETE CONTROL.
The lender can't demand the shares back, the borrower has no interest costs.
The shorted shares don't have voting power and don't get dividends but they add to
the market place float. It is obvious that the shorts have had control of the share price
of Avanir for a long time. Do you understand this??????

greatday, if they covered in one day, their position would be 2 mil long without any affect
on the share price. This scenario is an extreme example to show the effects of shorting
against the box. Collusion is against the law, but this could be common in spreading the risk
between a few institutions while controlling the price until the success or
failure of the company is apparent. The SEC does not require the major investors to show
their short positions as they do require them to report quarterly their long positions
(these guys claim doing so would give away their investment strategies).

Sentiment: Strong Buy

ray, let's say TRowe Price holds the whole 20 mil short (against the box) position.
This would give them control of 42 mil shares, enough to control the market. Their
risk does not fluctuate with the share price. They are only 2 mil long but control
42 mil shares. They only have to report their long position. What's not to like?

ray, I think when an institution shorts against the box with the goal of controlling the
market and limiting their risk, they don't give up their position at any price because there is
nothing to gain. When they see a clear road up, they will clear their short positions and
aggressively buy. Above their net zero position ($4.40), they S or get off the pot! The
major short position is probably spread among the top few (overall long) institutions.

Sentiment: Strong Buy

There is a pain market. Look at this week's Time magazine. Google: Time pain
The search for a good painkiller has always been frustrating. Opioids like Vicodin work great--except they're addictive. Acetaminophen (Tylenol) is powerful--but it can wreck your liver. Even aspirin, with all its known heart benefits, can lead to internal bleeding. Now there's more painful news for people suffering from conditions like severe arthritis: researchers have confirmed heart risks for those taking large doses of two popular nonsteroidal anti-inflammatory drugs (NSAIDs).

rim. if you want back in, PAY THE PRICE! Look's like you and ray
are locked out.

rim, you earlier said that you have been a trader in Avanir all along. All
you can hope for is volatility and being lucky jumping in and out.

Make sure they have a second (European) language and be willing to travel.

ray, you're sounding more and more like a revengeful
Dr Katz. You should back off showing too much medical ability.
Dr Katz always warned about his "safety concerns".
The "House of Cards" may be glued together by
"lucky science", like Abreva.

Sentiment: Strong Buy

ray, do you understand what a GSA contract is?
I worked in government procurement for five years!
I AM THE EXPERT HERE, NOT YOU!
Back away from your comments about the VA contract!

Sentiment: Strong Buy

Hi Sarge. I think we'll see the big drop in the short position when we cross $4.40,
that magical secondary offering price. I know I sound like a broken record (not the
Beatles), but the existing institutional shorts will switch tracks and start pushing the
bandwagon (playing our favorites).

Sentiment: Strong Buy

I was here in 1999 when Docosanol was FDA approved as an over the counter drug, just
after Dr Katz was replaced by Yakatan. We went to the AMEX exchange as AVN. I stuck
around betting on the mAb technology, then dropped out with N's first (as Dr Katz
warned on these boards) FDA rejection. I than came back at N's approval.
So I am relatively new as a steady investor.

Sentiment: Strong Buy

I'll be happy with $2.28. Will today's volume pass ray's 2 mil litmus test?
I think so.

Sentiment: Strong Buy

$4.40 is the point the short institutions would start losing money. That's the
reason for the $4.30 resistance. The last offering at $4.40 was mostly bought
by the institutions at which time they shorted against the box for insurance and
stock price control. No one else could have afforded this short for so long.
I agree that after we pass $4.40 (I think we'll need a shot in the arm) we'll fly.

Sentiment: Strong Buy